BioNTech Results Presentation Deck

BNT311: Next-generation bispecific antibody PD-L1x4-1BB MECHANISM OF ACTION OF Fc-SILENCED PD-L1×4-1BB BSABS ● ● 14 T cell TCR MHC-I/II + 4-1BB PD-1 PD-L1x4-1BB bsAbs PD-L1 PD-L1+ cell (tumor cell/APC) T M NK LOCAL LYMPH NODES PD-L1x4-1BB bsAbs Tumor cell Antigen-presenting cell T cell Myeloid cell Natural killer cell Macrophage APC T TUMOR NK NK Tu First-in-class, next generation checkpoint immunotherapy designed to enhance T cell and NK cell function through conditional 4-1BB co-stimulation while simultaneously blocking T cell axis Enhances proliferation and cytokine production of activated T cells, activates immune cells in tumor-draining lymph nodes, and induces tumor regression in vivo BIONTECH

View entire presentation